ReviewInternational journal of nanomedicine2026
Advancements in Nanomedicine for Precision Management of Lymphoma: Mechanisms, Diagnostics, and Therapeutic Strategies.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanomedicine-Empowered CAR-T Therapy for Multiple Myeloma: Toward Programmable, Durable, and Precision Immunotherapy.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymphoma is a heterogeneous malignancy originating from the lymphatic and hematopoietic systems. Traditional diagnostic and therapeutic approaches face significant limitations due to the complexity, dissemination, and drug resistance associated with lymphoma. Thus, novel approaches are required for precise management and treatment. Recently, advances in nanotechnology have provided new possibilities for lymphoma therapy, particularly through interdisciplinary research combining materials science and biomedicine, thus offering promising strategies for precision treatment. This review systematically summarizes recent advancements in nanomedicine for lymphoma management. First, it introduces mechanisms of nanotechnological interventions, emphasizing lymphoma's pathological features. Next, cutting-edge diagnostic applications, including extracellular vesicle detection, high-sensitivity nucleic acid biomarker sensing, and multimodal imaging, are highlighted. Additionally, emerging therapeutic strategies such as integrated nanoplatforms combining diagnostics, treatment, and real-time monitoring are discussed. Examples include optimized mRNA vaccine delivery, enhanced chimeric antigen receptor (CAR) T-cell therapy, bispecific nanoparticle systems, and combination gene/chemotherapy approaches. Finally, this review outlines the challenges associated with clinical translation and suggests future directions for intelligent adaptive nanomedicine, emphasizing its potential to significantly advance lymphoma diagnosis and therapeutic paradigms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.